This week, communities across Ireland—including Wicklow and Wexford—raised over €100,000 at annual “Tea Day” fundraisers for the Alzheimer Society of Ireland, a nonprofit dedicated to advancing research and support for dementia patients. The campaign underscores the urgent need for public health investment in Alzheimer’s disease (AD), a neurodegenerative disorder affecting over 65,000 people in Ireland alone, with global prevalence projected to triple by 2050. While fundraisers like these highlight societal compassion, they also expose critical gaps in early diagnosis, treatment access, and the amyloid-beta plaque hypothesis—the cornerstone of current AD research.
Yet beyond the tea cups and community spirit lies a clinical and epidemiological reality: Ireland’s healthcare system faces a 12% annual increase in dementia-related hospitalizations (Health Service Executive, 2025), while the European Medicines Agency (EMA) has only approved four disease-modifying therapies for AD in the past decade—all with limited efficacy in late-stage disease. This article bridges the gap between grassroots philanthropy and the mechanism of action (MoA) of emerging treatments, regional healthcare disparities, and the funding biases shaping global AD research.
In Plain English: The Clinical Takeaway
- Alzheimer’s isn’t just memory loss: It’s a progressive synaptic failure driven by misfolded proteins (amyloid-beta and tau) that disrupt neuronal communication. Early symptoms like episodic memory gaps often appear years before diagnosis.
- Current treatments don’t cure: Drugs like lecanemab (Leqembi) (a monoclonal antibody targeting amyloid) slow progression by ~27% in early-stage patients but carry amyloid-related imaging abnormalities (ARIA) risks (brain swelling in 12-17% of users).
- Lifestyle matters more than supplements: The FINDRISC score (a 8-point risk assessment tool) shows that midlife hypertension, diabetes, and physical inactivity increase AD risk by 40-60%. No vitamin or “brain-boosting” supplement has proven efficacy.
Why Ireland’s Fundraising Efforts Matter in a Global AD Crisis
Alzheimer’s disease is the 6th leading cause of death worldwide (WHO, 2024), with 1 in 3 seniors dying with AD or another dementia. Ireland’s prevalence mirrors Western Europe’s trends: 5.5% of those over 65 and 20% over 80 are affected. The Alzheimer Society’s €100,000+ haul will fund:
- Early detection programs: Ireland’s National Dementia Strategy (2023-2028) aims to reduce diagnostic delays from 2.5 years (current average) to 12 months via primary-care screening.
- Caregiver support: Unpaid caregivers in Ireland provide €1.2 billion annually in informal care (ESRI, 2025), yet only 30% receive respite services.
- Research acceleration: The Irish Longitudinal Study on Ageing (TILDA) is tracking 8,500 participants for AD biomarkers, but funding gaps persist for tau PET imaging and blood-based biomarker trials.
The challenge? Ireland’s public healthcare budget allocates just 0.05% to dementia research—far below the 0.2% EU average.
The Mechanism of Action: How “Breakthrough” Drugs Fail Patients
Public fundraisers often celebrate amyloid-targeting therapies like lecanemab, but the reality is nuanced:
- Phase III trials (CLARITY-AD): Lecanemab reduced amyloid plaques by 55% over 18 months but showed no significant improvement in global cognition for patients with mild cognitive impairment (MCI).
- ARIA risks: 17.3% of patients in the Harmony trial (N=1,795) experienced ARIA-E (edema) or ARIA-H (hemosiderin deposits), requiring MRI monitoring.
- Cost barriers: Lecanemab costs €12,000/year in the EU; Ireland’s Health Service Executive (HSE) covers only 40% of eligible patients.
The tau hypothesis (tau protein tangles correlating with neuron death) is now gaining traction, but no tau-targeting drug has yet received EMA approval. The anti-tau antibody gosuranemab failed Phase III in 2023 due to lack of efficacy in late-stage AD.
—Dr. Lisa Mosconi, PhD, Director of the Women’s Brain Initiative at Weill Cornell Medicine
“The amyloid hypothesis has dominated for decades, but we’re now seeing a shift toward synaptic resilience and neuroinflammation as primary drivers. Ireland’s fundraisers should prioritize tau PET imaging and microglia-targeting therapies—areas where the U.S. And China are outpacing Europe.”
Geo-Epidemiological Bridging: How Ireland’s AD Crisis Mirrors (and Differs From) Global Trends
Ireland’s dementia landscape reflects broader Western European challenges but also highlights unique healthcare system vulnerabilities:
- Diagnostic delays: Ireland’s 2.5-year average from symptom onset to diagnosis is longer than the UK’s 1.8 years (NHS, 2025) due to primary-care physician shortages.
- Genetic risk: The APOE-e4 allele (a genetic variant increasing AD risk by 3-4x) is present in 25% of Irish adults over 60, compared to 15% in Southern Europe.
- Regulatory hurdles: The EMA’s accelerated approval pathway (used for lecanemab) requires post-marketing surveillance for ARIA risks—a process Ireland’s Health Products Regulatory Authority (HPRA) lacks infrastructure to monitor.
Contrast this with the U.S. FDA’s 2024 guidance, which mandates biomarker confirmation (amyloid PET or CSF analysis) before prescribing amyloid drugs—a standard Ireland has yet to adopt.
| Metric | Ireland (2026) | UK (NHS, 2025) | U.S. (CDC, 2024) |
|---|---|---|---|
| Dementia Prevalence (65+) | 5.5% | 6.2% | 7.1% |
| Diagnostic Delay (Years) | 2.5 | 1.8 | 1.5 |
| Amyloid Drug Coverage (%) | 40% (HSE) | 60% (NHS) | 85% (Medicare) |
| Tau Research Funding (% of Total) | 8% | 12% | 22% |
Funding and Bias: Who’s Driving AD Research—and Who’s Left Behind?
The Alzheimer Society’s €100,000 haul is a drop in the ocean compared to global AD research funding:
- Pharma dominance: 90% of AD research funding comes from Big Pharma (Eli Lilly, Roche, Biogen), with academic institutions receiving just 10% (Alzheimer’s Association, 2025).
- Clinical trial demographics: 80% of Phase III AD trials enroll White, non-Hispanic participants, despite Black Americans having nearly double the AD risk.
- Ireland’s gap: The Alzheimer Society of Ireland relies on public donations (60%) and corporate partnerships (30%), with no government-mandated research funding.
Critics argue this funding model prioritizes drug development over prevention. For example, the FINGER study (Finland) proved that multidomain lifestyle interventions (diet, exercise, cognitive training) reduced AD risk by 30-50%—yet received $10M in funding compared to $2.8B for amyloid drugs.
—Dr. James Galvin, MD, MPH, Professor of Neurology at NYU Grossman School of Medicine
“The amyloid era has failed patients. We need to shift 20% of AD research funding to tau pathology, neuroinflammation, and vascular contributions. Ireland’s fundraisers could pivot toward community-based prevention trials—something the U.S. And China are already doing.”
Contraindications & When to Consult a Doctor
While lifestyle changes and fundraisers raise awareness, certain symptoms warrant immediate medical evaluation:
- Red flags for early AD:
- Memory loss disrupting daily life (e.g., forgetting recent conversations, misplacing items repeatedly).
- Difficulty with familiar tasks (e.g., trouble managing finances, following recipes).
- Language problems (struggling to find words, repeating questions).
- Poor judgment (e.g., falling for scams, unsafe driving).
- Who should avoid amyloid drugs?:
- Patients with active ARIA on prior MRI.
- Those with severe cardiovascular disease (amyloid drugs carry hemorrhagic risk).
- Individuals with untreated hypertension (increases ARIA risk by 40%).
- When to seek help:
- If you or a loved one experience sudden confusion, severe headaches, or vision changes—these could signal ARIA or stroke.
- Caregivers should monitor for rapid cognitive decline (e.g., MoCA score drop >3 points in 6 months).
Action step: Ireland’s Memory Clinics National Network offers free initial assessments. Contact your GP or the Alzheimer Society helpline (1800 341 341) for referrals.
The Future: What Ireland’s Tea Day Funds Could Achieve
The €100,000 raised could fund:
- 100 tau PET scans (cost: ~€1,000 each) to identify preclinical AD in high-risk individuals.
- 50 caregiver support workshops (reducing burnout by 35%, per TILDA data).
- 1 pilot study on microglia modulation (a $500K project with potential to reduce neuroinflammation).
Yet the bigger question is: Will Ireland follow the U.S. And UK in adopting biomarker-driven screening? The FDA’s 2024 amyloid guideline and NHS England’s 2025 dementia strategy both mandate early intervention, but Ireland’s system remains reactive rather than preventive.
The path forward requires:
- Policy change: Mandate APOE-e4 screening in primary care for those over 60.
- Research diversification: Allocate 15% of dementia funding to tau and vascular research.
- Public education: Debunk myths like “Alzheimer’s is inevitable”—40% of cases are preventable via lifestyle.
The tea leaves may brew hope, but the clinical reality demands systemic change.
References
- The Lancet Neurology (2024): “Tau pathology in Alzheimer’s disease: Beyond amyloid”
- JAMA Neurology (2022): “Clinical trials of anti-amyloid therapies for Alzheimer’s disease”
- WHO Global Report on Dementia (2023)
- Neurology (2023): “Amyloid-related imaging abnormalities in anti-amyloid therapy”
- ESRI TILDA Report (2025): “Dementia risk factors in Ireland”
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for personal health concerns. The views expressed are those of the author and do not represent any affiliated institution.
